Patrick Reville

24PUBLICATIONS
120CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)AutoimmunityRegenerative medicine (incl. stem cells)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

|Jul 09, 2025
An Isoform-Specific RUNX1C-BTG2 Axis Governs AML Quiescence and Chemoresistance.

Cuijuan Han, Zhiping Zhang, Edie I Crosse

|Jun 13, 2025
Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy-Ineligible Patients With Isocitrate Dehydrogenase-Mutated AML.

Courtney D DiNardo, Jennifer Marvin-Peek, Sanam Loghavi

|Apr 08, 2025
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis.

Naval Daver, Jayastu Senapati, Hagop M Kantarjian

|Apr 03, 2025
Blood-based proteomic profiling identifies OSMR as a novel biomarker of AML outcomes.

Patrick K Reville, Bofei Wang, Jennifer Marvin-Peek

|Mar 31, 2025
Mutation dynamics from diagnosis to relapse in acute myeloid leukemia with chromosomal 7 deletions.

Eitan Kugler, Enes Dasdemir, Alex Bataller

|Mar 16, 2025
Superior preclinical efficacy of co-treatment with BRG1/BRM and FLT3 inhibitor against AML cells with FLT3 mutations.

Warren Fiskus, Christopher P Mill, Jessica Piel

Pageof 4

Frequent Collaborators

18 joint publications

Naval G Daver

17 joint publications

Courtney DiNardo

14 joint publications

Koji Sasaki

13 joint publications

Tapan M Kadia